Compare abrdn Physical Palladium Shares ETF (PALL) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
abrdn Physical Palladium Shares ETF vs State Street SPDR S&P Biotech ETF — how do they compare? abrdn Physical Palladium Shares ETF trades at $23.33, while State Street SPDR S&P Biotech ETF trades at $152.12. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, abrdn Physical Palladium Shares ETF nearer its low. Which is the better fit depends on your goals.
| PALL | XBI | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Broad Market / Factor |
52-Week High | $37.18 | $164.28 |
52-Week Low | $19.96 | $85.16 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PALL trades at $22.80, up 0.44% on the day, with a bearish technical signal from moving averages. The stock recently underwent a 1:5 forward split effective May 18, 2026. Recent news highlights palladium's underperformance in the precious metals rally, with some analysts viewing current price weakness as a potential buying opportunity due to supply risks and industrial demand.
The outlook for PALL hinges on a recovery in palladium prices, with sentiment mixed. Opportunities exist if industrial demand strengthens and supply constraints materialize, but risks include continued commodity price volatility and broader economic pressures that could dampen demand.
XBI trades at $150.94, down 2.14% today, with technical indicators showing a bearish trend but oversold RSI suggesting potential near-term support. The ETF lacks traditional valuation metrics due to its structure, but recent news highlights strong biotech sector momentum, including a 17% monthly gain and robust M&A activity. Analyst coverage is limited to a single hold rating, reflecting cautious optimism amid sector volatility.
Outlook: Biotech sector tailwinds from M&A and AI-driven drug discovery offer upside, but high volatility and policy risks persist. Investors should weigh XBI's equal-weight exposure to small/mid-cap biotech against its elevated beta, with technical support near $149 critical for short-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About abrdn Physical Palladium Shares ETF
PALL is a physically-backed ETF that tracks the spot price of palladium. It holds physical bullion in secure vaults, offering a liquid way to invest in this precious metal primarily used in automotive catalytic converters and electronics.
Read more on PALL →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
